TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Shares of organ transplant innovator TransMedics Group ( TMDX -1.41%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...

Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate ...

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

Jan. 13, 2025 /PRNewswire/ -- TransMedics Group ... and misleading claims made in a short-seller report issued by Scorpion Capital on January 10, 2025. In response, the company issued the ...

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.

The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the“Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics ...